Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience

類似資料

• 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
  著者:: Cameron, David, 等
  出版事項: (2017)
• Disease-Free Survival According to Degree of HER2 Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial
  著者:: Dowsett, Mitch, 等
  出版事項: (2009)
• Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial
  著者:: Lambertini, Matteo, 等
  出版事項: (2020)
• A Pooled Analysis of the Cardiac Events in the Trastuzumab Adjuvant Trials
  著者:: de Azambuja, Evandro, 等
  出版事項: (2019)
• PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer?
  著者:: Pondé, Noam, 等
  出版事項: (2019)